July 23, 2025

FDA Grants Breakthrough Status to Melanoma Test

The FDA has granted Breakthrough Device designation to Castle Biosciences’ DecisionDx-Melanoma test, a gene expression profile assay designed to improve risk stratification and personalized care in cutaneous melanoma.

Conexiant

July 21, 2025

Melanoma Risk Differs by Mole Count and Genetic Profile

A large study found distinct genetic and phenotypic risk patterns for nevus-associated and de novo invasive melanomas.

Conexiant

July 16, 2025

New Guidelines Target Preventive Gaps in Inflammatory Bowel Disease

New clinical recommendations detail updated vaccination and screening protocols to reduce infection and cancer risks in adults with inflammatory bowel disease, particularly those on immune-modifying therapies.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

April 17, 2023

Single-Agent Pembrolizumab May Benefit Patients With Advanced Desmoplastic Melanoma

Monotherapy with pembrolizumab led to clinical responses in 89% of patients with unresectable metastatic desmoplastic melanoma, according to results from the phase II S1512 clinical trial presented by...

The ASCO Post

April 30, 2024

Model for Predicting Survival Following SLNB in Melanoma

Researchers have developed a model for the prediction of recurrence-free and melanoma-specific survival after sentinel lymph node biopsy (SLNB) in patients with melanoma.

Conexiant

April 29, 2024

Adjuvant mRNA-Based Personalized Therapy Plus Immunotherapy in High-Risk Resected Melanoma

The addition of a novel mRNA-based individualized neoantigen therapy to pembrolizumab may improve recurrence-free survival in patients with completely resected high-risk cutaneous melanoma.

Conexiant

August 21, 2023

Ipilimumab Plus Nivolumab May Improve Outcomes in Patients With Refractory Metastatic Melanoma, Study Suggests

Researchers have discovered that ipilimumab in combination with nivolumab may be an effective second-line therapy in patients with PD-1 blockade–refractory metastatic melanoma, according to a recent s...

The ASCO Post

May 07, 2024

What’s Keeping the US From Allowing Better Sunscreens?

Examine the FDA's stringent sunscreen regulations and the impact on the availability of advanced sunscreen ingredients in the U.S., as well as bipartisan legislative efforts to modernize these standards.

KFF Health News